
jul pm et
summari compani leader pharmaceut medic devic consum product
nm price-to-earnings oper ep
risk assess reflect view
product larg immun econom cycl
reli singl product categori
custom sustain growth enjoy
competit advantag owe substanti financi
resourc busi scale global sale capabl
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
retain
actelion market drug mainli treat
hypertens late stage compound
actelion discoveri stage oper
spun new compani own
option acquir anoth
actelion expect accret earn
first year
see solid pharmaceut
growth consum product medic
devic continu rebound aid sale
rule remicad patent invalid
like result lower remicad sale
nonetheless think remicad maintain
sizeabl market share due physician
prefer biosimilar inflectra
approv interchang
product overal see remicad sale
fall
see ep think
near-term profit hurt
signific increas spend state
plan invest
capit invest
prior four-year
recommend buy view
uniqu situat unmatch depth
breadth ever-grow global health care
market solid posit drug
medic devic consum product
also favor view pipelin
juli tremfya approv treat
psoriasi see sale billion
may reiter goal
new blockbust drug
line extens
million sale potenti februari
erleada apalutamid treat prostat cancer
approv expect file
esketamin treatment-resist
depress late said would
stop seek global approv sirukumab
treat rheumatoid arthriti fda
request safeti data
risk recommend target
includ price pressur pipelin failur
sizeabl judgment lawsuit
target price
ep estim slightli peer
view pipelin posit see robust
pharmaceut sale along improv
sale medic devic unit
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
member execut
corpor overview johnson johnson rank one largest diversifi health care
firm product span across pharmaceut medic devic industri compani
also major particip global consum product busi sale account
overal sale
pharmaceut segment sale includ product therapeut area includ
immunolog neurolog oncolog pain manag urolog virolog product within
pharmaceut unit includ remicad sale billion stelara billion simponi
billion zytiga billion invega sustenna billion imbruvica billion xarelto
billion howev note best sell drug remicad lost patent protect januari
 appeal rule remicad patent invalid think result lower
remicad sale howev biosimilar remicad name inflectra approv
interchang product result think physician continu prefer prescrib
medic devic diagnost segment sale sell wide rang product
includ ethicon wound care surgic sport medicin women health care product cordi
orthopaed joint reconstruct spinal product vistakon dispos contact lens sold
ortho clinic diagnost profession diagnost product carlyl group billion
largest acquisit medic devic segment billion acquisit synth inc
consum segment sale primarili sell person care product includ
nonprescript drug adult skin hair care product babi care product oral care product first aid
product women health product nutrit product major brand includ band-aid brand
adhes bandag imodium a-d anti-diarrh johnson babi line product neutrogena skin
hair care product tylenol pain reliev
corpor strategi johnson johnson oper compani sell product
across globe despit size highli innov view seek maintain leadership
posit aggress fund new product develop spend total billion
repres sale -- billion sale may
drug late-stag develop seven phase trial fda review new recent
launch includ prezista hiv xaralto acut coronari syndrom invega schizophrenia zytiga
prostat cancer invokana type diabet imbruciva leukemia novemb fda
approv olysio treatment chronic hepat may reiter goal new
blockbust drug line extens million
annual sale blockbust drug drug gener billion annual sale
excit new therapi includ new treatment diabet cancer immun disord infecti diseas
neuropath disord
although intern growth key object compani also pursu strateg acquisit
januari acquir acclar firm work new devic treat ear nose throat
condit decemb acquisit consum health care busi ad lead
brand listerin nicorett lubriderm visin neosporin sudaf zantac benadryl
mid-jun acquir synth billion cash stock swiss maker skelet
fixat implant orthoped product synth earn million sale billion
although regul requir divest trauma busi complet deal still think
deal significantli enhanc global reach innov orthoped provid import
oper synergi think effect fund entir acquisit via oversea domicil
cash stock portion financ indirectli oversea cash
import acquisit recent year includ crucel dutch maker vaccin micru
endovascular maker devic treat stroke cougar biotechnolog firm engag
anti-cancer drug mentor corp supplier aesthet product maker
biosurg immunotherapi product conor medsystem produc cobalt chromium
coronari stent incorpor innov drug deliveri technolog juli acquir vogu
llc privately-held develop manufactur hair care person care
product billion june acquir billion retain
actelion market drug mainli treat hypertens late stage compound actelion discoveri
stage oper spun new compani own option acquir
financi trend sale grown billion billion repres
compound annual growth rate adjust ep grown
aid stock buyback repres compound annual growth rate
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc juli technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook pharmaceut
sub-industri next month neutral
although issu high drug price remain
overhang industri believ
impact lessen believ
trump administr push
regulatori chang forc drug price
may trump administr releas
drug price blueprint american patient
first view offer littl polici
regulatori chang rein escal drug
price rather see consolid
amongst largest drug purchas
health insur pharmaci benefit manag
hospit effort increas buy
firm announc rais
price drug year
signific portion firm organ
follow june drug price
innov work group draft
execut order aim tackl high drug
price draft focus reduc regul
method increas competit lower
intellectu properti right scale back
discount given hospit serv lower
incom patient import note mani
individu serv work group
former pharmaceut execut
like cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
also see expand sale new
innov drug therapi margin
improv accru cost restructur
merger synergi
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
juli pharmaceut
declin vs rise
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share johnson johnson
keep target slightli peer
ep estim remain posit divers
product improv devic sale also rais ep ep
vs estim sale growth
forecast declin advers fx state
pend actelion acquisit on-track close inclus
actelion see ep sale
/jeffrey loo cfa
et capit iq keep buy opinion share johnson
 johnson agre acquir actelion
pharmaceut share billion subject approv
retain actelion commercially-market drug mainli treat
hypertens late stage compound actelion discoveri stage oper
spun-off separ compani own option
acquir anoth although actelion immedi add
sale expect accret earn
first full year think pay signific premium
et capit iq keep buy opinion share johnson
 johnson trim target
peer revis ep estim
set ep vs forecast sale
rose billion billion forecast pharma sale
slightli miss expect guid organ growth
rate see ep see
improv sale consum product medic devic anticip
deceler growth pharma also plan sell medic devic
analyst research note compani news
juri st loui missouri rule
asbestos-ovarian cancer link relat babi powder juri award
billion women claim develop ovarian cancer use
babi powder shower-to-show anoth talc-bas product
allegedli contamin asbesto deni babi powder
contamin asbesto appeal rule although see
case lead numer addit case relat asbesto babi powder
link believ mani year case reach final
conclus talc/babi powder lawsuit file
sever result juri decis see
overhang share howev compani success appeal
abl overturn rule /jeffrey loo cfa
et cfra keep buy opinion share johnson johnson
keep target peer
ep estim faster growth ep vs in-lin
estim sale fx benefit rose
growth forecast cost rose higher expect
growth broad-bas domest sale intern sale
fx benefit consum sale rose pharmaceut
sale aid contribut actelion acquisit rose
medic devic sale rose encourag stabil
medic devic robust pharmaceut sale driven increas
oncolog sale strong uptak darzalex imbruvica zytiga
note sale remicad fell due higher discount rebat amid
biosimilar competit see continu weak throughout also
announc plan increas spend due benefit
et cfra reiter buy opinion share johnson
johnson rais target
peer ep estim set
ep vs in-lin estim sale aid
acquisit rose robust pharmaceut sale
medic devic rose consum product encourag
robust pharmaceut sale oncolog immunolog infecti
diseas rebound medic devic see continu
guid sale ep
et cfra keep buy opinion share johnson johnson
rais target slightli
peer forward ep estim rais
ep estim ep vs
ahead estim sale aid recent actelion
acquisit rose organ growth pharma rose
consum rose devic aid abbott optic deal rose nda
submit apalutamid treat prostat cancer seek
approv sirukumab discontinu develop talacotuzumab /jeffrey
et cfra keep buy opinion share johnson johnson
rais target peer
forward ep estim view jnj pipelin
favor ep vs ahead estim rais
ep estim sale rose
pharma sale fell partli declin remicad
biosimilar competit see sale acceler recent actelion
acquisit recent approv tremfya rais sale guidanc
ep
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
